Iranian Journal of Microbiology 2017. 9(6):318-323.

Prevalence of Acinetobacter baumannii bacteremia in intensive care units of Ibn Rochd University Hospital, Casablanca
Assiya El Kettani, Fakhreddine Maaloum, Idrissa Diawara, Khalid Katfy, Nadia Harrar, Khalid Zerouali, Houria Belabbes, Naima Elmdaghri


Background and Objectives: Acinetobacter baumannii bacteremia are grave because of the multi-resistance of the organism to antibiotics. This study aimed to determine the prevalence of A. baumannii isolated from blood cultures and to describe their antibiotic resistance patterns.

Materials and Methods: A retrospective longitudinal study was conducted on blood cultures between 2010 and 2014 from all Ibn Rochd University Hospital intensive care units; it was based on the exploitation of microbiology laboratory database (duplicates were excluded). Isolation and identification of A. baumannii were performed according to standard techniques of bacteriology and susceptibility testing as recommended by the CLSI. PCR was used to detect β-Lactamase genes,
blaOXA-51, blaOXA-23.

Results: Among the 4232 samples received at the laboratory, 2402 (56.8%) were positive. Negative coagulase Staphylococcus was isolated in 21.6% of cases followed by A. baumannii (9.2%), and K. pneumoniae (9.1%). A. baumannii strains were resistant to most antibiotics tested: imipenem (75.7%), ceftazidim (85.4%), cefotaxim (98.6%), gentamicin (78.1%), amikacin (63.5%) and ciprofloxacin (88.2%). All A. baumannii strains, resistant to carbapenem, tested were positive for blaOXA-51 genes and 87.5% expressed the blaOXA-23 genes.

Conclusion: A. baumannii was the second germ frequently isolated from blood cultures in intensive care units. It was multi-resistant to antibiotics. The strengthening of hospital hygiene measures and surveillance of antibiotic resistance is needed to limit the spread of germs and to optimize the management of antibiotics.


Acinetobacter baumannii; Bacteremi; Antibiotic resistance; blaOXA-51; blaOXA-23

Full Text:



Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no eskape! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12.

Lee HY, Chen CL, Wu SR, Huang CW, Chiu CH. Risk factors and outcome analysis of Acinetobacter baumannii complex bacteremia in critical patients. Crit Care Med 2014;42:1081-1088.

Esterly J S, Griffith M, Qi C, Malczynski M, Postelnick M J, Scheetz M H. Impact of carbapenem resistance and receipt of active antimicrobial therapy on cinical outcomes of Acinetobacter baumannii bloodstream infections. Antimicrob Agents Chemother 2011; 55: 4844-4849.

Rumbo C, Gato E, Lopez M, Ruiz de Alegria C, Fernandez-Cuenca F, Martinez-Martinez L, et al. Contribution of efflux pumps, porins, and β-lactamases to multidrug resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 2013;57:5247-5245.

Higgins PG, Lehmann M, Wisplinghoff H, Seifert H. gyrB Multiplex PCR To Differentiate between Acinetobacter calcoaceticus and Acinetobacter genomic species. J Clin Microbiol 2010;48:4592-4594.

Sandle T, Babenko D, LavrinenkoA, Azizov I, Cheşcǎ A. The current state of PCR approach in detection and identification of carbapanem hydrolysis β-lactamases genes. EJPPS 2014; 19:153-164.

Falagas ME, Kopterides P. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect 2006; 64:7-15.

Zhou HY, Yuan Z, Du YP. Prior use of four invasive procedures increases the risk of Acinetobacter baumannii nosocomial bacteremia among patients in intensive care units: a systematic review and meta-analysis. Int J Infect Dis 2014;22:25-30.

Hassoune S, Nani S, Ouhadous M, Aalloula O, Benbachir M, Maaroufi A. Incidence des bactériémies nosocomiales dans les services à haut risque du centre hospitalier universitaire de Casablanca (Maroc). Prat Organ Soins 2012;43(1):19-24.

Le groupe Rémic de la Société Française de Microbiologie. Rémic Référentiel en microbiologie médicale 4ème édition 2010.

Réseau d’alerte, d’investigation et de surveillance des infections nosocomiales (Raisin). Enquête nationale de prévalence des infections nosocomiales et des traitements anti-infectieux en établissements de santé, France, mai-juin 2012.

Thabet L, Zoghlami A, Boukadida J, Ghanem A, Messadi AA. Comparative study of antibiotic resistance in bacteria isolated from burned patients during two periods (2005-2008, 2008-2011) and in two hospitals (Hospital Aziza Othmana, Trauma and Burn Center). Tunis Med 2013; 91:134-138.

Elhani D, Elhani I, Aouni M. Résistance chez les bacilles gram négatif. Où en sommes nous? Tunis Med 2012; 90: 680-685.

Bakour S, Touati A, Sahli F, Ameur AA, Haouchine D, Rolain JM. Antibiotic resistance determinants of multidrug-resistant Acinetobacter baumannii clinical isolates in Algeria. Diagn Microbiol Infect Dis 2013;76:529-531.

Ehlers MM, Hughes JM, Kock MM. Prevalence of Carbapenemases in Acinetobacter baumannii. INTECH Open Access Publisher 2012.

Ciftci IH, Asik G, Karakece E, Oksuz L, Yagci S, Sesli Cetin E, et al. Distribution of blaOXA genes in Acinetobacter baumannii strains: a multicenter study. Mikrobiyol Bul 2013;47:592-602.

Higgins P, Dammhayn C, Hackel M, Seifert H. Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2010; 65: 233-238.

Villegas MV, Kattan JN, CorreaA,Lolans K, Guzman A. M, Woodford N, et al. Dissemination of Acinetobacter baumannii Clones with OXA-23 Carbapenemase in Colombian Hospitals. Antimicrob Agents Chemother 2007;51:2001-2004.

Merkier A, Catalano M, Ramirez MS, Quiroga C, Orman B, Ratier L, et al. Polyclonal spread of blaOXA-23 and blaOXA-58 in Acinetobacter baumannii isolates from Argentina. J Infect Dev Ctries 2008; 2: 235-240.

Carvalho KR, Carvalho-Assef APDA, Peirano G, Dos Santos LCG, Pereira MJF, Asensi MD. Dissemination of multidrug-resistant Acinetobacter baumannii genotypes carrying blaOXA-23 collected from hospitals in Rio de Janeiro, Brazil. Int J Antimicrob Agents 2009; 34: 25-28.

SchimithBier KE, Luiz SO, Scheffer MC, Gales AC, Paganini MC, Nascimento AJ, Carignano E, et al. Temporal evolution of carbapenem-resistant Acinetobacter baumannii in Curitiba, southern Brazil. Am J Infect Control 2010; 38: 308-314.

Peleg A, Seifert H, Paterson D. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21: 538-582.

Opazo A, Domínguez M, Bello H, Amyes SGB, González-Rocha G. OXA-type carbapenemases in Acinetobacter baumannii in South America. J Infect Dev Ctries 2012; 6:311-316.

Fishbain J, Peleg AY. Treatment of Acinetobacter Infections. Clin Infect Dis 2010;51:79-84.


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.